Viking Therapeutics stock jumps 16% after drugmaker moves weight loss injection to late-stage trial

It brings the San Diego-based company one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. Shares of both Novo Nordisk and Eli Lilly fell around 2% in premarket trading Thursday. But after receiving written feedback from the Food and Drug Administration, the company has decided to move the injection directly into a phase three trial, CEO Brian Lian said during an earnings call on Wednesday. That decision will like ...